文献速递认知障碍与痴呆

确定临床前阿尔茨海默病的临床意义衰退

Determining clinically meaningful decline in preclinical Alzheimer disease.
PubMed 文献 · Neurology · 2019-07-09

该研究基于3个国际队列的1120名认知正常个体,估计β-淀粉样蛋白(Aβ)状态与多认知域纵向变化的关系,并评估Aβ与基线因素的交互作用。结果显示Aβ+认知正常者平均6年后认知表现接近轻度认知障碍(MCI)水平;模拟4年试验中,假设25%疗效需每组2000人达到80%把握度。

要点

  • 认知正常Aβ+者平均6年认知表现接近早期MCI水平。
  • 延缓衰退40%-50%可将临床相关损害延迟3年。
  • 假设25%疗效的4年试验需每组2000人达到80%把握度。

核心结论

  • 临床前AD人群在6年内认知表现衰退至早期MCI水平。
  • 将衰退速度减缓40%-50%可使临床相关损害延迟3年。
  • 假设25%疗效时,4年试验需每组2000人达到80%把握度。

研究设计与样本

  • 研究纳入来自3个国际队列的1120名认知正常个体。
  • 估计Aβ状态与多认知域纵向变化的关系,并评估Aβ与基线因素的交互作用。
  • 进行把握度分析,探索样本量随疗效变化的规律。

主要发现

  • 认知正常Aβ+参与者平均在基线后6年认知表现接近MCI水平。
  • 模拟4年治疗试验中,假设25%疗效,达到80%把握度需每组2000名参与者。
  • 多个因素与Aβ交互预测认知衰退,但发现均具有队列特异性。
  • 尽管队列设计存在差异,大样本和足够随访时间下Aβ+组在认知复合指标上一致下降。

临床怎么用

  • 临床前AD试验设计需准备比当前考虑更大规模的样本和更长随访时间。
  • 假设25%疗效时,4年试验需每组2000人达到80%把握度。
  • 延缓衰退40%-50%可延迟临床相关损害3年,可能是有意义的疗效。

局限性

  • 与Aβ状态的交互作用不一致,不易推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the time required for a preclinical Alzheimer disease population to decline in a meaningful way, use estimates of decline to update previous clinical trial design assumptions, and identify factors that modify β-amyloid (Aβ)-related decline. METHODS: In 1,120 cognitively unimpaired individuals from 3 international cohorts, we estimated the relationship between Aβ status and longitudinal changes across multiple cognitive domains and assessed interactions between Aβ and baseline factors. Power analyses were performed to explore sample size as a function of treatment effect. RESULTS: Cognitively unimpaired Aβ+ participants approach mild cognitive impairment (MCI) levels of performance 6 years after baseline, on average. Achieving 80% power in a simulated 4-year treatment trial, assuming a 25% treatment effect, required 2,000 participants/group. Multiple factors interacted with Aβ to predict cognitive decline; however, these findings were all cohort-specific. Despite design differences across the cohorts, with large sample sizes and sufficient follow-up time, the Aβ+ groups declined consistently on cognitive composite measures. CONCLUSIONS: A preclinical AD population declines to the cognitive performance of an early MCI population in 6 years. Slowing this rate of decline by 40%-50% delays clinically relevant impairment by 3 years-a potentially meaningful treatment effect. However, assuming a 40%-50% drug effect highlights the difficulties in preclinical AD trial design, as a more commonly assumed treatment effect of 25% results in a required sample size of 2,000/group. Designers of preclinical AD treatment trials need to prepare for larger and longer trials than are currently being considered. Interactions with Aβ status were inconsistent and not readily generalizable.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Insel PS, Weiner M, Mackin RS, et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology. 2019. PMID: 31289148. doi:10.1212/WNL.0000000000007831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。